Optimal method for metabolic tumour volume assessment of cervical cancers with inter-observer agreement on [18F]-fluoro-deoxy-glucose positron emission tomography with computed tomography.
Cervix
FDG
MTV
PET/CT
Tumour segmentation
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
01
07
2020
accepted:
24
11
2020
pubmed:
15
12
2020
medline:
29
5
2021
entrez:
14
12
2020
Statut:
ppublish
Résumé
Cervical cancer metabolic tumour volume (MTV) derived from [18F]-FDG PET/CT has a role in prognostication and therapy planning. There is no standard method of outlining MTV on [18F]-FDG PET/CT. The aim of this study was to assess the optimal method to outline primary cervical tumours on [18F]-FDG PET/CT using MRI-derived tumour volumes as the reference standard. 81 consecutive cervical cancer patients with pre-treatment staging MRI and [18F]-FDG PET/CT imaging were included. MRI volumes were compared with different PET segmentation methods. Method 1 measured MTVs at different SUV For method 1, the MTV MTV
Identifiants
pubmed: 33313962
doi: 10.1007/s00259-020-05136-8
pii: 10.1007/s00259-020-05136-8
pmc: PMC8113292
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2009-2023Subventions
Organisme : Cancer Research UK
ID : 12783
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/J007986/1
Pays : United Kingdom
Références
Ferlay J, et al. Global cancer observatory: cancer today. Lyon France: International Agency for Research on Cancer. 2018. Available from: https://gco.iarc.fr/today . Accessed 21 Nov 2018.
Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
Chung HH, et al. Prognostic value of metabolic tumor volume measured by FDG-PET/CT in patients with cervical cancer. Gynecol Oncol. 2011;120(2):270–4.
pubmed: 21109300
Khan SR, Rockall AG, Barwick TD. Molecular imaging in cervical cancer. Q J Nucl Med Mol Imaging. 2016;60(2):77–92.
pubmed: 26859085
Han S, et al. Prognostic value of volume-based metabolic parameters of (18)F-FDG PET/CT in uterine cervical cancer: a systematic review and meta-analysis. AJR Am J Roentgenol. 2018;211(5):1112–21.
pubmed: 30207790
Kidd EA, et al. FDG-PET-based prognostic nomograms for locally advanced cervical cancer. Gynecol Oncol. 2012;127(1):136–40.
pubmed: 22735785
pmcid: 3991305
Mahantshetty U, et al. Magnetic resonance image-based dose volume parameters and clinical outcome with high dose rate brachytherapy in cervical cancers--a validation of GYN GEC-ESTRO brachytherapy recommendations. Clin Oncol (R Coll Radiol). 2011;23(5):376–7.
Haie-Meder C, et al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother Oncol. 2005;74(3):235–45.
pubmed: 15763303
Potter R, et al. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiother Oncol. 2006;78(1):67–77.
pubmed: 16403584
Miller TR, Grigsby PW. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated by radiation therapy. Int J Radiat Oncol Biol Phys. 2002;53(2):353–9.
pubmed: 12023139
Ho KC, et al. Correlation of apparent diffusion coefficients measured by 3T diffusion-weighted MRI and SUV from FDG PET/CT in primary cervical cancer. Eur J Nucl Med Mol Imaging. 2009;36(2):200–8.
pubmed: 18779960
Ma DJ, Zhu JM, Grigsby PW. Tumor volume discrepancies between FDG-PET and MRI for cervical cancer. Radiother Oncol. 2011;98(1):139–42.
pubmed: 20971521
Upasani MN, et al. 18-fluoro-deoxy-glucose positron emission tomography with computed tomography-based gross tumor volume estimation and validation with magnetic resonance imaging for locally advanced cervical cancers. Int J Gynecol Cancer. 2012;22(6):1031–6.
pubmed: 22622949
Sun H, et al. Anatomical and functional volume concordance between FDG PET, and T2 and diffusion-weighted MRI for cervical cancer: a hybrid PET/MR study. Eur J Nucl Med Mol Imaging. 2014;41(5):898–905. https://doi.org/10.1007/s00259-013-2668-4 .
doi: 10.1007/s00259-013-2668-4
pubmed: 24463908
Zhang S, et al. Defining PET tumor volume in cervical cancer with hybrid PET/MRI: a comparative study. Nucl Med Commun. 2014;35(7):712–9.
pubmed: 24709983
Lai AYT, et al. Concordance of FDG PET/CT metabolic tumour volume versus DW-MRI functional tumour volume with T2-weighted anatomical tumour volume in cervical cancer. BMC Cancer. 2017;17(1):825.
pubmed: 29207964
pmcid: 5718076
Cegla P, et al. The effect of different segmentation methods on primary tumour metabolic volume assessed in (18)F-FDG-PET/CT in patients with cervical cancer, for radiotherapy planning. Contemp Oncol (Pozn). 2019;23(3):183–6.
Boellaard R, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(2):328–54.
pubmed: 25452219
Boellaard R, et al. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med. 2004;45(9):1519–27.
pubmed: 15347719
Krak NC, et al. Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial. Eur J Nucl Med Mol Imaging. 2005;32(3):294–301.
pubmed: 15791438
Frings V, et al. Repeatability of metabolically active volume measurements with 18F-FDG and 18F-FLT PET in non-small cell lung cancer. J Nucl Med. 2010;51(12):1870–7.
Akkas BE, et al. Do clinical characteristics and metabolic markers detected on positron emission tomography/computerized tomography associate with persistent disease in patients with in-operable cervical cancer? Ann Nucl Med. 2013;27(8):756–63.
pubmed: 23793926
Kidd EA, et al. Changes in cervical cancer FDG uptake during chemoradiation and association with response. Int J Radiat Oncol Biol Phys. 2013;85(1):116–22.
pubmed: 22520475
Sun Y, Lu P, Yu L. The volume-metabolic combined parameters from (18)F-FDG PET/CT may help predict the outcomes of cervical carcinoma. Acad Radiol. 2016;23(5):605–10.
pubmed: 26853968
Hong JH, et al. Prognostic value of total lesion glycolysis measured by 18F-FDG PET/CT in patients with locally advanced cervical cancer. Nucl Med Commun. 2016;37(8):843–8.
pubmed: 27058362
Burger IA, et al. (18)F-FDG PET/CT of non–small cell lung carcinoma under neoadjuvant chemotherapy: background-based adaptive-volume metrics outperform TLG and MTV in predicting Histopathologic response. J Nucl Med. 2016;57(6):849–54.
pubmed: 26823566
pmcid: 5510547
Hatt M, et al. Classification and evaluation strategies of auto-segmentation approaches for PET: report of AAPM task group no. 211. Med Phys. 2017;44(6):e1–e42.
pubmed: 5902038
pmcid: 5902038
Soussan M, et al. Relationship between tumor heterogeneity measured on FDG-PET/CT and pathological prognostic factors in invasive breast cancer. PLoS One. 2014;9(4):e94017.
pubmed: 24722644
pmcid: 3983104
Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med. 2007;48(6):932–45.
pubmed: 17504879
Werner-Wasik M, et al. What is the best way to contour lung tumors on PET scans? Multiobserver validation of a gradient-based method using a NSCLC digital PET phantom. Int J Radiat Oncol Biol Phys. 2012;82(3):1164–71.
pubmed: 21531085
Dimopoulos JC, et al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (IV): basic principles and parameters for MR imaging within the frame of image based adaptive cervix cancer brachytherapy. Radiother Oncol. 2012;103(1):113–22.
pubmed: 22296748
pmcid: 3336085
Jung DC, et al. The validity of tumour diameter assessed by magnetic resonance imaging and gross specimen with regard to tumour volume in cervical cancer patients. Eur J Cancer. 2008;44(11):1524–8.
pubmed: 18573655
Armitage P, Berry G, Matthews JNS. Statistical methods in medical research. 4th ed. Wiley-Blackwell; 2001.
Koo TK, Li MY. A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med. 2016;15(2):155–63.
pubmed: 27330520
pmcid: 4913118
Prat J. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2014;124(1):1–5.
pubmed: 24219974
Kidd EA, et al. Cervical cancer histology and tumor differentiation affect 18F-fluorodeoxyglucose uptake. Cancer. 2009;115(15):3548–54.
pubmed: 19472399
Lin Y, et al. Opportunities for 2-[(18)F] fluoro-2-deoxy-D-glucose PET/CT in cervical-vaginal neuroendocrine carcinoma: case series and literature review. Korean J Radiol. 2012;13(6):760–70.
pubmed: 23118575
pmcid: 3484297
Wanet M, et al. Gradient-based delineation of the primary GTV on FDG-PET in non-small cell lung cancer: a comparison with threshold-based approaches, CT and surgical specimens. Radiother Oncol. 2011;98(1):117–25.
pubmed: 21074882
Narayan K, et al. Estimation of tumor volume in cervical cancer by magnetic resonance imaging. Am J Clin Oncol. 2003;26(5):e163–8.
pubmed: 14528092
Burger IA, et al. PET quantification with a histogram derived total activity metric: superior quantitative consistency compared to total lesion glycolysis with absolute or relative SUV thresholds in phantoms and lung cancer patients. Nucl Med Biol. 2014;41(5):410–8.
pubmed: 24666719
pmcid: 4455601
Fujii S, et al. Volume measurement by diffusion-weighted imaging in cervical cancer. Yonago Acta Med. 2017;60(2):113–8.
pubmed: 28701894
pmcid: 5502223
Dimopoulos JC, et al. Inter-observer comparison of target delineation for MRI-assisted cervical cancer brachytherapy: application of the GYN GEC-ESTRO recommendations. Radiother Oncol. 2009;91(2):166–72.
pubmed: 19062118
Kim HJ, Kim W. Method of tumor volume evaluation using magnetic resonance imaging for outcome prediction in cervical cancer treated with concurrent chemotherapy and radiotherapy. Radiat Oncol J. 2012;30(2):70–7.
pubmed: 22984685
pmcid: 3429891
Bettinardi V, et al. PET quantification: strategies for partial volume correction. Clin Transl Imaging. 2014;2:199–218.
Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. Radiology. 2016;278(2):563–77.
pubmed: 26579733
Taha AA, Hanbury A. Metrics for evaluating 3D medical image segmentation: analysis, selection, and tool. BMC Med Imaging. 2015;15(1):29.
pubmed: 26263899
pmcid: 4533825
Schramm G, et al. Quantitative accuracy of attenuation correction in the Philips Ingenuity TF whole-body PET/MR system: a direct comparison with transmission-based attenuation correction. Magma. 2013;26(1):115–26.
pubmed: 22923020
Zaidi H, et al. Design and performance evaluation of a whole-body Ingenuity TF PET-MRI system. Phys Med Biol. 2011;56(10):3091–106.
pubmed: 21508443
pmcid: 4059360
Chen SW, et al. Textural features of cervical cancers on FDG-PET/CT associate with survival and local relapse in patients treated with definitive chemoradiotherapy. Sci Rep. 2018;8(1):11859.
pubmed: 30089896
pmcid: 6082904